| Oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents AS Darvesh, RT Carroll, A Bishayee, WJ Geldenhuys, CJ Van der Schyf Expert review of neurotherapeutics 10 (5), 729-745, 2010 | 279 | 2010 |
| Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells JA Gaasch, PR Lockman, WJ Geldenhuys, DD Allen, CJ Van der Schyf Neurochemical research 32, 1196-1208, 2007 | 260 | 2007 |
| Pharmacology and structure‐activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives WJ Geldenhuys, SF Malan, JR Bloomquist, AP Marchand, ... Medicinal research reviews 25 (1), 21-48, 2005 | 244 | 2005 |
| Curcumin and neurodegenerative diseases: a perspective AS Darvesh, RT Carroll, A Bishayee, NA Novotny, WJ Geldenhuys, ... Expert opinion on investigational drugs 21 (8), 1123-1140, 2012 | 218 | 2012 |
| Optimizing the use of open-source software applications in drug discovery WJ Geldenhuys, KE Gaasch, M Watson, DD Allen, CJ Van der Schyf Drug discovery today 11 (3-4), 127-132, 2006 | 191 | 2006 |
| Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers W Geldenhuys, T Mbimba, T Bui, K Harrison, V Sutariya Journal of drug targeting 19 (9), 837-845, 2011 | 186 | 2011 |
| Molecular determinants of blood–brain barrier permeation WJ Geldenhuys, AS Mohammad, CE Adkins, PR Lockman Therapeutic delivery 6 (8), 961-971, 2015 | 142 | 2015 |
| Role of serotonin in Alzheimer’s disease: a new therapeutic target? WJ Geldenhuys, CJ Van der Schyf CNS drugs 25 (9), 765-781, 2011 | 134 | 2011 |
| In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery AS Darvesh, RT Carroll, WJ Geldenhuys, GA Gudelsky, J Klein, ... Expert opinion on drug discovery 6 (2), 109-127, 2011 | 119 | 2011 |
| Targeting the blood-brain barrier to prevent sepsis-associated cognitive impairment DC Nwafor, AL Brichacek, AS Mohammad, J Griffith, BP Lucke-Wold, ... Journal of central nervous system disease 11, 1179573519840652, 2019 | 113 | 2019 |
| Multifunctional drugs with different CNS targets for neuropsychiatric disorders CJ Van der Schyf, WJ Geldenhuys, MBH Youdim Journal of neurochemistry 99 (4), 1033-1048, 2006 | 113 | 2006 |
| Paclitaxel–hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model RK Mittapalli, X Liu, CE Adkins, MI Nounou, KA Bohn, TB Terrell, ... Molecular cancer therapeutics 12 (11), 2389-2399, 2013 | 112 | 2013 |
| The emergence of designed multiple ligands for neurodegenerative disorders WJ Geldenhuys, MBH Youdim, RT Carroll, CJ Van der Schyf Progress in neurobiology 94 (4), 347-359, 2011 | 109 | 2011 |
| Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs J Joubert, WJ Geldenhuys, CJ Van der Schyf, DW Oliver, HG Kruger, ... ChemMedChem 7 (3), 375-384, 2012 | 108 | 2012 |
| Molecular insights into human monoamine oxidase B inhibition by the glitazone antidiabetes drugs C Binda, M Aldeco, WJ Geldenhuys, M Tortorici, A Mattevi, ... ACS medicinal chemistry letters 3 (1), 39-42, 2012 | 107 | 2012 |
| mitoNEET as a novel drug target for mitochondrial dysfunction WJ Geldenhuys, TC Leeper, RT Carroll Drug discovery today 19 (10), 1601-1606, 2014 | 103 | 2014 |
| Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders RT Carroll, D Bhatia, W Geldenhuys, R Bhatia, N Miladore, A Bishayee, ... Journal of drug targeting 18 (9), 665-674, 2010 | 101 | 2010 |
| Rationally designed multi-targeted agents against neurodegenerative diseases W J Geldenhuys, C J Van der Schyf Current medicinal chemistry 20 (13), 1662-1672, 2013 | 100 | 2013 |
| NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia A Mdzinarishvili, WJ Geldenhuys, TJ Abbruscato, U Bickel, J Klein, ... Neuroscience letters 383 (1-2), 49-53, 2005 | 100 | 2005 |
| Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke A Mdzinarishvili, V Sutariya, PK Talasila, WJ Geldenhuys, P Sadana Drug delivery and translational research 3, 309-317, 2013 | 95 | 2013 |
